Palma Rocchi

Responsable de groupe Directrice de Recherche (DR) INSERM
Voir les publications Voir le mail Tel : 0491223664
Equipe
Groupe
Publications
Apr 2010 Oncogene

Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.

Andrieu C, Taieb D, Baylot V, Ettinger S, Soubeyran P, De-Thonel A, Nelson C, Garrido C, So A, Fazli L, Bladou F, Gleave M, Iovanna JL, Rocchi P

Oct 2011 Cell death & disease

OGX-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer.

Baylot V, Andrieu C, Katsogiannou M, Taieb D, Garcia S, Giusiano S, Acunzo J, Iovanna J, Gleave M, Garrido C, Rocchi P

Dec 2012 Molecular therapy : the journal of the American Society of Gene Therapy

Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer.

Baylot V, Katsogiannou M, Andrieu C, Taieb D, Acunzo J, Giusiano S, Fazli L, Gleave M, Garrido C, Rocchi P

Sep 2017 Oncotarget

Targeting Hsp27/eIF4E interaction with phenazine compound: a promising alternative for castration-resistant prostate cancer treatment.

Ziouziou H, Andrieu C, Laurini E, Karaki S, Fermeglia M, Oueslati R, Taieb D, Camplo M, Siri O, Pricl S, Katsogiannou M, Rocchi P

May 2018 Journal of nuclear medicine : official publication, Society of Nuclear Medicine

PSMA-Targeted Radionuclide Therapy and Salivary Gland Toxicity: Why Does It Matter?

Taïeb D, Foletti JM, Bardiès M, Rocchi P, Hicks RJ, Haberkorn U

Jun 2018 Oncotarget

Correction: Targeting Hsp27/eIF4E interaction with phenazine compound: a promising alternative for castration-resistant prostate cancer treatment.

Ziouziou H, Andrieu C, Laurini E, Karaki S, Fermeglia M, Oueslati R, Taieb D, Camplo M, Siri O, Pricl S, Katsogiannou M, Rocchi P

Jan 2019 PloS one

Integrative proteomic and phosphoproteomic profiling of prostate cell lines.

Katsogiannou M, Boyer JB, Valdeolivas A, Remy E, Calzone L, Audebert S, Rocchi P, Camoin L, Baudot A

Voir toutes les publications